SPDR S&P Biotech ETF Sees $140.8 Million in Outflows
In the latest week, the SPDR S&P Biotech ETF (Symbol: XBI) has experienced a significant shift in shares outstanding, with an outflow of approximately $140.8 million. This represents a decrease of 2.8% from 63,000,000 shares to 61,225,000 shares.
Current Performance of Key Holdings
Among the major components of XBI, today’s performance reflects mixed results: EXACT Sciences Corp. (Symbol: EXAS) has risen by about 0.5%, while Neurocrine Biosciences, Inc. (Symbol: NBIX) has fallen by approximately 1.2%. Natera Inc. (Symbol: NTRA) shows an increase of around 0.8%. For a detailed list of holdings, please visit the XBI Holdings page.
Price Performance Overview
The chart below illustrates the one-year price performance of XBI compared to its 200-day moving average:
XBI’s 52-week range highlights a low of $66.66 per share and a high of $105.47. The last trade was registered at $78.89. Analyzing the share price against the 200-day moving average can also provide valuable technical insights.
Understanding ETF Dynamics
Exchange-traded funds (ETFs) operate similarly to stocks; however, investors buy and sell ‘units’ instead of shares. These units can be freely traded and also created or destroyed based on investor demand. Each week, we track changes in shares outstanding to identify ETFs with significant inflows or outflows. New unit creation requires purchasing the underlying assets, whereas unit destruction necessitates selling those assets, which can influence the individual components within the ETF.
For more insights, click here to discover which nine other ETFs have recently faced notable outflows.
Explore Additional Resources:
- ETFs Holding AOS
- Schlumberger Technical Analysis
- Funds Holding CBAN
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
